PRIVO TECHNOLOGIES, LLC
Peabody, MA · Medtech · Private
PRV111, a nano-engineered patch delivering cisplatin chemotherapy directly to oral tumors and regional lymph nodes
- Grants
- $24M
- 20 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · FAST TRACK: IND Enabling Studies for Oral Cancer | $293,491 | |
| Federal grant | Department of Health and Human Services · Phase II · FAST TRACK: IND Enabling Studies for Oral Cancer | $960,707 | |
| Federal grant | Department of Health and Human Services · Phase II · Customized Nanotechnology Based Treatment of Oral Cancer | $999,997 | |
| Federal grant | Department of Health and Human Services · Phase II · Customized Nanotechnology Based Treatment of Oral Cancer | $265,000 | |
| Federal grant | Department of Health and Human Services · Phase II · FAST TRACK: IND Enabling Studies for Oral Cancer | $1,170,342 | |
| Federal grant | Department of Health and Human Services · Phase II · Customized Nanotechnology Based Treatment of Oral Cancer | $999,997 | |
| Federal grant | Department of Health and Human Services · Phase II · Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer | $3,185,684 | |
| Federal grant | Department of Health and Human Services · Phase II · Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer | $98,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer | $1,083,847 | |
| Federal grant | Department of Health and Human Services · Phase II · Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer | $4,318 | |
| Federal grant | Department of Health and Human Services · Phase II · Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer | $1,000,447 | |
| Federal grant | Department of Health and Human Services · Phase II · Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy | $5,211,701 | |
| Federal grant | Department of Health and Human Services · Phase II · Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy | $779,005 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings | $401,107 | |
| Federal grant | Department of Health and Human Services · Phase II · Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy | $984,664 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings | $987,292 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings | $1,012,303 | |
| Federal grant | Department of Health and Human Services · Phase II · Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer) | $2,084,026 | |
| Federal grant | Department of Health and Human Services · Phase II · Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer) | $1,245,681 | |
| Federal grant | Department of Health and Human Services · Phase II · Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer) | $1,170,285 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2088 | ALTYX SURGICAL, INC. | — | — |
| 2089 | REDWOOD NEURO INC. | — | — |
| 2090 | CLEAR GENE INC | — | — |
| 2091 | PRIVO TECHNOLOGIES, LLC | — | — |
| 2092 | XL Sci Tech Inc | — | — |
| 2093 | VDF INDUSTRIES INC | — | — |
| 2094 | Cognext Diagnostics LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.